Cargando…

Can we use a simple blood test to reduce unnecessary adverse effects from radiotherapy by timely identification of radiotherapy-resistant rectal cancers? MeD-Seq rectal study protocol

BACKGROUND: Chemoradiation therapy (CRT) followed by surgery is currently the standard of care to treat patients with locally advanced rectal cancer (LARC). CRT reduces local recurrences, but is associated with significant damage to the surrounding healthy tissue that can severely impact patients qu...

Descripción completa

Detalles Bibliográficos
Autores principales: Mens, D. M., van Rees, J. M., Wilting, S. M., Verhoef, C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10696698/
https://www.ncbi.nlm.nih.gov/pubmed/38049783
http://dx.doi.org/10.1186/s12885-023-11671-y
_version_ 1785154622615191552
author Mens, D. M.
van Rees, J. M.
Wilting, S. M.
Verhoef, C.
author_facet Mens, D. M.
van Rees, J. M.
Wilting, S. M.
Verhoef, C.
author_sort Mens, D. M.
collection PubMed
description BACKGROUND: Chemoradiation therapy (CRT) followed by surgery is currently the standard of care to treat patients with locally advanced rectal cancer (LARC). CRT reduces local recurrences, but is associated with significant damage to the surrounding healthy tissue that can severely impact patients quality of life. Additionally, a proportion of patients (hardly) benefit from CRT. We aim to develop a diagnostic innovation, using DNA-methylation, which can enable a more selective and thereby more effective use of the available therapies for rectal cancer patients. METHODS: MeD-Seq Rectal is a prospective single centre, observational study. 75 patients diagnosed with rectal cancer and will receive CRT as neoadjuvant treatment are will be included. DNA-methylation profiling will be performed on liquid biopsies to predict pathological response to CRT. DISCUSSION: To data no clinical or image-based features were found that predict response to CRT. we hypothesize that DNA methylation patterns in liquid biopsies may provide a promising and patient-friendly strategy to predict CRT resistance upfront. TRIAL REGISTRATION: This trial is registered at ClinicalTrials.gov (NCT06035471).
format Online
Article
Text
id pubmed-10696698
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-106966982023-12-06 Can we use a simple blood test to reduce unnecessary adverse effects from radiotherapy by timely identification of radiotherapy-resistant rectal cancers? MeD-Seq rectal study protocol Mens, D. M. van Rees, J. M. Wilting, S. M. Verhoef, C. BMC Cancer Study Protocol BACKGROUND: Chemoradiation therapy (CRT) followed by surgery is currently the standard of care to treat patients with locally advanced rectal cancer (LARC). CRT reduces local recurrences, but is associated with significant damage to the surrounding healthy tissue that can severely impact patients quality of life. Additionally, a proportion of patients (hardly) benefit from CRT. We aim to develop a diagnostic innovation, using DNA-methylation, which can enable a more selective and thereby more effective use of the available therapies for rectal cancer patients. METHODS: MeD-Seq Rectal is a prospective single centre, observational study. 75 patients diagnosed with rectal cancer and will receive CRT as neoadjuvant treatment are will be included. DNA-methylation profiling will be performed on liquid biopsies to predict pathological response to CRT. DISCUSSION: To data no clinical or image-based features were found that predict response to CRT. we hypothesize that DNA methylation patterns in liquid biopsies may provide a promising and patient-friendly strategy to predict CRT resistance upfront. TRIAL REGISTRATION: This trial is registered at ClinicalTrials.gov (NCT06035471). BioMed Central 2023-12-04 /pmc/articles/PMC10696698/ /pubmed/38049783 http://dx.doi.org/10.1186/s12885-023-11671-y Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Study Protocol
Mens, D. M.
van Rees, J. M.
Wilting, S. M.
Verhoef, C.
Can we use a simple blood test to reduce unnecessary adverse effects from radiotherapy by timely identification of radiotherapy-resistant rectal cancers? MeD-Seq rectal study protocol
title Can we use a simple blood test to reduce unnecessary adverse effects from radiotherapy by timely identification of radiotherapy-resistant rectal cancers? MeD-Seq rectal study protocol
title_full Can we use a simple blood test to reduce unnecessary adverse effects from radiotherapy by timely identification of radiotherapy-resistant rectal cancers? MeD-Seq rectal study protocol
title_fullStr Can we use a simple blood test to reduce unnecessary adverse effects from radiotherapy by timely identification of radiotherapy-resistant rectal cancers? MeD-Seq rectal study protocol
title_full_unstemmed Can we use a simple blood test to reduce unnecessary adverse effects from radiotherapy by timely identification of radiotherapy-resistant rectal cancers? MeD-Seq rectal study protocol
title_short Can we use a simple blood test to reduce unnecessary adverse effects from radiotherapy by timely identification of radiotherapy-resistant rectal cancers? MeD-Seq rectal study protocol
title_sort can we use a simple blood test to reduce unnecessary adverse effects from radiotherapy by timely identification of radiotherapy-resistant rectal cancers? med-seq rectal study protocol
topic Study Protocol
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10696698/
https://www.ncbi.nlm.nih.gov/pubmed/38049783
http://dx.doi.org/10.1186/s12885-023-11671-y
work_keys_str_mv AT mensdm canweuseasimplebloodtesttoreduceunnecessaryadverseeffectsfromradiotherapybytimelyidentificationofradiotherapyresistantrectalcancersmedseqrectalstudyprotocol
AT vanreesjm canweuseasimplebloodtesttoreduceunnecessaryadverseeffectsfromradiotherapybytimelyidentificationofradiotherapyresistantrectalcancersmedseqrectalstudyprotocol
AT wiltingsm canweuseasimplebloodtesttoreduceunnecessaryadverseeffectsfromradiotherapybytimelyidentificationofradiotherapyresistantrectalcancersmedseqrectalstudyprotocol
AT verhoefc canweuseasimplebloodtesttoreduceunnecessaryadverseeffectsfromradiotherapybytimelyidentificationofradiotherapyresistantrectalcancersmedseqrectalstudyprotocol